MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530008 | Name: Antineoplaston A 10

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Antineoplaston A 10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

Chemical Structure

Antineoplaston A 10
Antineoplaston A 10
CAS#91531-30-5

Theoretical Analysis

MedKoo Cat#: 530008

Name: Antineoplaston A 10

CAS#: 91531-30-5

Chemical Formula: C13H14N2O3

Exact Mass: 246.1000

Molecular Weight: 246.27

Elemental Analysis: C, 63.40; H, 5.73; N, 11.38; O, 19.49

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ANP-A-10; ANPA-10; ANP A 10; ANPA 10;
IUPAC/Chemical Name
N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide
InChi Key
OQGRFQCUGLKSAV-JTQLQIEISA-N
InChi Code
InChI=1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)/t10-/m0/s1
SMILES Code
O=C(N[C@@H](CC1)C(NC1=O)=O)CC2=CC=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 246.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Qu XJ, Cui SX, Tian Z, Li X, Chen MH, Xu WF, Inagaki Y, Deng YB, Makuuchi M, Nakata M, Tang W. Induction of apoptosis in human hepatocellular carcinoma cells by synthetic antineoplaston A10. Anticancer Res. 2007 Jul-Aug;27(4B):2427-31. PubMed PMID: 17695534. 2: Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D. 2003;4(2):91-101. PubMed PMID: 12718563. 3: Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D. 2004;5(6):315-26. PubMed PMID: 15563234. 4: Badria F, Mabed M, El-Awadi M, Abou-Zeid L, Al-Nashar E, Hawas S. Immune modulatory potentials of antineoplaston A-10 in breast cancer patients. Cancer Lett. 2000 Aug 31;157(1):57-63. PubMed PMID: 10893443. 5: Badria F, Mabed M, Khafagy W, Abou-Zeid L. Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Lett. 2000 Jul 3;155(1):67-70. PubMed PMID: 10814881. 6: Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H. Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Kurume Med J. 1996;43(2):137-47. PubMed PMID: 8755117. 7: Fujii T, Nakamura AM, Yokoyama G, Yamaguchi M, Tayama K, Miwa K, Toh U, Kawamura D, Shirouzu K, Yamana H, Kuwano M, Tsuda H. Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells. Oncol Rep. 2005 Aug;14(2):489-94. PubMed PMID: 16012735. 8: Kumabe T, Tsuda H, Uchida M, Ogoh Y, Hayabuchi N, Sata M, Nakashima O, Hara H. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep. 1998 Nov-Dec;5(6):1363-7. PubMed PMID: 9769368. 9: Choi BG, Kim OY, Chung BH, Cho WJ, Cheon SH, Choi SU, Lee CO. Synthesis of antineoplaston A10 analogs as potential antitumor agents. Arch Pharm Res. 1998 Apr;21(2):157-63. PubMed PMID: 9875424. 10: Choi BG, Seo HK, Chung BH, Choi SU, Lee CO. Synthesis of Mannich bases of antineoplaston A10 and their antitumor activity. Arch Pharm Res. 1994 Dec;17(6):467-9. PubMed PMID: 10319160. 11: Ogata Y, Matono K, Shirouzu K. [Anti-proliferative effects of biochemical defense modifier antineoplaston in colorectal carcinoma]. Nihon Rinsho. 2003 Sep;61 Suppl 7:505-9. Japanese. PubMed PMID: 14574945. 12: Ashraf AQ, Liau MC, Kampalath BN, Burzynski SR. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs Exp Clin Res. 1987;13 Suppl 1:45-50. PubMed PMID: 3569015. 13: Ogata Y, Matono K, Tsuda H, Ushijima M, Uchida S, Akagi Y, Shirouzu K. Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer. PLoS One. 2015 Mar 19;10(3):e0120064. doi: 10.1371/journal.pone.0120064. PubMed PMID: 25790229; PubMed Central PMCID: PMC4366171. 14: Michalska D. Theoretical investigations on the structure and potential binding sites of antineoplaston A10 and experimental findings. Drugs Exp Clin Res. 1990;16(7):343-9. PubMed PMID: 2092960. 15: Tsuda H. Inhibitory effect of antineoplaston A-10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. The members of Antineoplaston Study Group. Kurume Med J. 1990;37(2):97-104. PubMed PMID: 2175003. 16: Tsuda H, Sugihara S, Nishida H, Hara H, Eriguchi N, Ishii K, Sasaki K, Yoshimura S, Tanaka N. The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma. Jpn J Cancer Res. 1992 May;83(5):527-31. PubMed PMID: 1377669. 17: Ashraf AQ, Liau MC, Mohabbat MO, Burzynski SR. Preclinical studies on antineoplaston A10 injections. Drugs Exp Clin Res. 1986;12 Suppl 1:37-45. PubMed PMID: 3743379. 18: Xu W, Wang H, Yuan Y. Pharmacokinetic study of radioactive antineoplaston A10 in rats and mice. Drugs Exp Clin Res. 1990;16(7):351-5. PubMed PMID: 2092961. 19: Muldoon TG, Copland JA, Lehner AF, Hendry LB. Inhibition of spontaneous mouse mammary tumour development by antineoplaston A10. Drugs Exp Clin Res. 1987;13 Suppl 1:83-8. PubMed PMID: 3569021. 20: Wang H, Xu W, Yuan Y. Studies of the release rate and bioavailability of antineoplaston A10 capsule. Drugs Exp Clin Res. 1990;16(7):357-9. PubMed PMID: 2092962.